https://www.selleckchem.com/pr....oducts/tertiapin-q.h
The incidence of motion restricting heterotopic ossification at 10 yr was not significantly different from 7 yr for 1-level (30.7%vs 29.6%) or 2-level (41.7%vs 39.2%) patients. Only 2 subsequent surgeries were reported after 7 yr. Our results through 10 yr were comparable to 7-yr outcomes, demonstrating that CDA with Mobi-C continues to be a safe and effective surgical treatment for patients with 1- or 2-level cervical degenerative disc disease. Our results through 10 yr were comparable to 7-yr outcomes, demonstrating that CDA with
Like
Comment
Share
